NCT03815279
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03815279
Title A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) (iStopMM)
Acronym iStopMM
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors Landspitali University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries ISL

Facility Status City State Zip Country Details
Landspitali University Hospital Reykjavik 101 Iceland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field